Lenalidomide Market Growth Analysis By 2024-2032
Lenalidomide Market Size, Industry Analysis Report, 2024-2032

Lenalidomide Market Share, Size, Trends, Industry Analysis Report, By Type (5mg,10mg,15mg,25mg); By Application; By End-User; By Dosage; By Region; Segment Forecast, 2024 - 2032

  • Published Date:Feb-2024
  • Pages: 118
  • Format: PDF
  • Report ID: PM4437
  • Base Year: 2023
  • Historical Data: 2019 – 2022

Report Outlook

Lenalidomide Market size was valued at USD 10.39 billion in 2023. The market is anticipated to grow from USD 10.86 billion in 2024 to USD 15.67 billion by 2032, exhibiting the CAGR of 4.7% during the forecast period.

Market Overview

The increasing research innovations in the pharmaceutical space to innovate new therapies and medications for existing diseases, primarily cancer, are highly supporting the growth of the lenalidomide market size in the world. The growing research advancements in this area are likely to stimulate the lenalidomide market in the long run.

●      For instance, in December 2023, the results of the phase 3 trial of a research study funded by the European Myeloma Network along with Janssen Research and Development suggested that multiple myeloma patients who received daratumumab in combination with lenalidomide, dexamethasone (VRd), and bortezomib showed superior results in terms of efficacy compared to those who took VRd alone.

Moreover, the prevalence of cancer cases in the global space necessitates the need for suitable drug medication. According to the pharmaceutical company Johnson & Johnson, the number of cases of blood cancer in the world has risen by more than 125% since 1990. As this trend continues further, there will be a significant demand for lenalidomide in the foreseeable future.

Lenalidomide Market Size

To Understand More About this Research: Request a Free Sample Report

However, the lower supply of lenalidomide in the marketplace is attributable to the presence of patent rights, and the existence of licenses among pharmaceutical companies to produce limited quantities hinders the growth of the global market.

Growth Drivers

The rising incidence of multiple myeloma

The increasing prevalence of multiple myeloma is contributing significantly to the growth of the Lenalidomide market industry forecast. Several driving factors underscore this upward trend, including the rising awareness and diagnosis of multiple myeloma cases worldwide. Lenalidomide, an effective treatment option for this hematologic malignancy, is witnessing heightened demand as a result. Additionally, advancements in medical research and technology, coupled with an aging population, are further fueling the market expansion. The drug's proven efficacy, coupled with its approval for various therapeutic applications, positions Lenalidomide as a key player in addressing the rising incidence of multiple myeloma and underscores its crucial role in the pharmaceutical landscape.

The increasing research studies on developing new ways of having lenalidomide

Pharmaceutical firms and researchers are highly interested in exploring new ways of taking lenalidomide apart from orally. In January 2024, Starton Therapeutics announced the positive results of its STAR-LLD Phase 1b clinical trials for multiple myeloma. It tested the effectiveness of administration of low-dose lenalidomide through subcutaneous drugs along with bortezomib and dexamethasone. The results of the study are expected to come in the third quarter of 2024. This ongoing study is expected to drive new growth opportunities for the lenalidomide market size.

Restraining Factors

Higher costs of drug development

The side effects associated with lenalidomide, such as an irregular heartbeat, thrombosis, chest pain, bleeding gums, and more, are expected to impact the growth of lenalidomide during the forecast timeframe negatively. Furthermore, the higher initial costs of drug development and competition from generic medicines are expected to hinder lenalidomide market growth in the long run.

Report Segmentation

The market is primarily segmented based on type, application, end-user, dosage and region.

By Type

By Application

By End-User

By Dosage

By Region

  • 5mg Capsules
  • 10mg Capsules
  • 15mg Capsules
  • 25mg Capsules
  • Multiple myeloma (MM)
  • Myelodysplastic syndromes (MDS)
  • Lymphoma
  • Others

 

  • Hospitals
  • Cancer Treatment Centers
  • Research Institutes

 

 

  • Capsules
  • Tablets
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Type Analysis

10mg segment is expected to witness the highest growth during the forecast period

The 10mg segment is likely to grow at a higher CAGR during the study period, primarily driven by its flexibility in dosage. In some cases, doctors are required to test the patient's condition for cancer and are likely to offer a lower dose to avoid overdose consequences initially. Furthermore, the emergence of combination therapies in the marketplace and ongoing research activities are positively driving segmental growth, as this task necessitates the need for lower-dose drugs.

The 15-mg segment led the industry market with optimal revenue share in 2023, largely attributable to its ability to assist doctors in planning optimized treatment dosages for patients.

By Application Analysis

Multiple Myeloma segment accounted for the largest market share in 2023

The multiple myeloma segment accounted for the largest market share in 2023 and is expected to enhance its market position throughout the study period. The rising prevalence of cancer cases, primarily multiple myeloma, and the superior performance of lenalidomide in treating these diseases are boosting lenalidomide market opportunities. A 2023 study published in Spandidos publications reviewed the potential capability of this drug in cancer myeloma treatment.

The myelodysplastic syndromes segment is expected to witness significant growth over the next few years on account of the ongoing use of lenalidomide in dealing with patients suffering from myelodysplastic syndromes.

By End-User Analysis

Hospital segment held the significant market revenue share in 2023

The hospital segment held a significant share in 2023, due to the continuous rise in the number of cancer patients taking admissions. The increased awareness about cancer, primarily blood cancer, is driving doctor consultations and boosting demand for lenalidomide by healthcare providers.

By Dosage Analysis

Capsule segment witnessed a dominant share in the global market in 2023

The capsule segment registered the dominant share in the world market in 2023 and is projected to continue its growth trajectory over the study period. The dosage mostly depends on its formulation, doctor consultation, available medication, and process of production. However, most of the major players are offering capsules due to their higher solubility. The increased accessibility of lenalidomide capsules is a driving factor in this segmental growth.

Regional Insights

North America region registered the largest share of the global market in 2023

The North America region dominated the market. This is attributed to the presence of larger players in the lenalidomide market size. For instance, in September 2022, Dr. Reddy Laboratories introduced Revlimid to the United States market. The increasing number of companies entering this market is one of the major factors contributing to the larger share of the global market.

The Asia Pacific will grow at the fastest pace during the forecast period, owing to the growing prevalence of cancer cases in the region. According to the 2020 available statistics, cancer is one of the major causes of mortality in the world, with around ten million deaths. According to the WHO South-East region report, there are estimated 2.2 million new cases of cancer and 1.4 million cancer-related death rates, contributing to more than 1 in 10 deaths in the region. As this trend continues further, there will be significant demand potential in the future, according to the lenalidomide market forecast.

Key Market Players & Competitive Insights

Strategic expansion activities to drive the competition

The lenalidomide market is moderately competitive with the presence of several players in the market. The rising strategic collaborations, expansion activities, and settlements in patent licencing among the major players are anticipated to witness significant growth during the forecast timeframe. For instance, in September 2022, Zydus unveiled lenalidomide capsules in the United States.

Some of the major players operating in the global market include:

  • Ablynx (Belgium)
  • Actiza (India
  • Celgene (US)
  • Celltrion (South Korea)
  • Dexa Medical (Indonesia)
  • Exova (UK)
  • LEO Pharma (Denmark)
  • Natco Pharma (India)
  • Toyama Chemical (Japan)

Recent Developments in the Industry

  • In September 2022, Lotus introduced lenalidomide capsules in 14 European countries through its partners and expected to unveil them in more than 90 countries along with its commercial network around the world by 2024.
  • In February 2022, Sandoz, a manufacturer of generic drugs, unveiled lenalidomide in 19 more countries in Europe.

Report Coverage

The lenalidomide market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.

The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, type, application, end-user, dosage and their futuristic growth opportunities.

Lenalidomide Market Report Scope

Report Attributes

Details

Market size value in 2024

USD 10.86 billion

Revenue forecast in 2032

USD 15.67 billion

CAGR

4.7% from 2024 – 2032

Base year

2023

Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments covered

  • By Type
  • By Application
  • By End-User
  • By Dosage
  • By Region

Regional scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape

  • Lenalidomide Market Share Analysis (2023)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments

Report Format

  • PDF + Excel

Customization

Report customization as per your requirements with respect to countries, region and segmentation.

Want to check out the Lenalidomide Market report before buying it? Then, our sample report has got you covered. It includes key market data points, ranging from trend analyses to industry estimates and forecasts. See for yourself by downloading the sample report. 

Browse Our Top Selling Reports

Camping Coolers Market Size, Share 2024 Research Report
Clinical Communication and Collaboration Market Size, Share 2024 Research Report
Coin Operated Laundries Market Size, Share 2024 Research Report
Plastics in Electrical and Electronics Market Size, Share 2024 Research Report
Australia Facial Injectables Market Size, Share 2024 Research Report
 

FAQ's

The global lenalidomide market size is expected to reach USD 15.67 billion by 2032

Key players in the market are Ablynx, Actiza, Celgene, Celltrion, Dexa Medical, Exova, LEO Pharma

North America contribute notably towards the global Lenalidomide Market

Lenalidomide Market exhibiting the CAGR of 4.7% during the forecast period.

The Lenalidomide Market report covering key segments are type, application, end-user, dosage and region.